Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-06-02

FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Solco Healthcare US, LLC)

View source ↗

Summary

FDA approved a supplemental application for a generic fixed-dose combination of irbesartan and hydrochlorothiazide for hypertension, manufactured by Solco Healt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide)

Snippet

SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)